Alcon Purchases Dry Eye Medication from Kala Pharmaceuticals

The vision care company Alcon is moving into the dry eye disease market with its purchase of two medications from Kala Pharmaceuticals. Kala sold its dry-eye drug Eysuvis and post-operative ocular pain drug Inveltys to Alcon for $60 million upfront, alongside future milestone payments. The two drugs were made possible by Kala’s formulation technology that enables drug delivery to mucus-laden ocular tissue.

According to Amber Tong of Endpoints News, “Particularly with Eysuvis, which consists of a corticosteroid called loteprednol etabonate, the biotech promised to offer a therapy that acts quicker than systemic corticosteroids and offers a stronger effect than over-the-counter eye drops. Despite earlier mixed data, the drug ultimately induced a statistically significant improvement in ocular discomfort severity while also meeting a secondary goal of conjunctival hyperemia in a final Phase III trial.”

To read more, click here.

(Source: Endpoints News, May 23^rd, 2022)